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	 Simple,	 selective	 and	 precise	 spectrophotometric	 methods	 were	 adopted	 for	 simultaneous
determination	of	sitagliptin	(SIT)	and	simvastatin	(SIM)	in	new	co‐formulated	pharmaceutical
dosage	form.	In	the	first	method,	SIT	was	determined	by	measuring	its	zero	order	absorbance
at	266.4	nm	in	the	range	of	40‐360	µg/mL	in	the	presence	of	up	to	70%	of	SIM.	While,	the	two
cited	drugs	were	determined	simultaneously	using	third	derivative	method	by	measuring	the
sum	of	peak	amplitudes	(peak	&	valley)	at	275.3‐280.3	nm	and	240.5‐244.7	nm	in	the	ranges
of	 40‐360	µg/mL	and	 2‐18	µg/mL	 for	 SIT	 and	 SIM,	 respectively.	 In	 the	 second	method,	 the
first	derivative	of	ratio	spectra	method	was	applied	by	measuring	the	peak	height	at	255.9	and
275.2	nm	using	18	µg/mL	SIM	as	devisor	over	a	concentration	range	of	40‐360	µg/mL	of	SIT
and	at	228.3,	240.5	and	248	nm	using	100	µg/mL	of	SIT	as	divisor	over	a	concentration	range
2‐18	µg/mL	SIM.	 In	 the	 third	method	 the	 ratio	 subtraction	spectrophotometric	method	was
used,	where	SIM	can	be	determined	by	dividing	the	spectra	of	the	mixtures	by	the	spectrum	of
SIT	 (40	 µg/mL)	 followed	by	 subtracting	 the	 constant	 absorbance	 value	of	 the	plateau,	 then
finally	multiply	the	produced	spectrum	by	the	spectrum	of	the	devisor.	Laboratory	prepared
mixtures	were	 successfully	 tried	 for	 the	 three	compositions	of	 tablets	 (10,	20	and	40	mg	of
SIM)	 with	 100	 mg	 of	 SIT.	 The	 developed	 methods	 were	 validated	 as	 per	 International
Conference	of	Harmonization	guidelines.	
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1.	Introduction	
	
Sitagliptin	 (SIT),	 (R)‐4‐oxo‐4‐[3‐(trifluoromethyl)‐5,	
dihydro[1,2,4]triazolo[4,3‐a]pyrazin‐7(8H)‐yl]‐1‐(2,4,5‐
trifluorophenyl)	butan‐2‐amine,	is	an	oral	dipeptidyl	peptidase‐
4	 (DPP‐4)	 inhibitor,	 which	 improves	 glycaemic	 control	 by	
inhibiting	 DPP‐4	 inactivation	 of	 the	 incretin	 hormones	
glucagon‐like	 peptide‐1	 (GLP‐1)	 and	 glucose‐dependent	
insulinotropic	 polypeptide	 (GIP)	 (Figure	 1).	 This	 increases	
active	incretin	and	insulin	levels	and	decreases	glucagon	levels	
and	post‐glucose‐load	glucose	excursion	[1,2].		
Simvastatin	(SIM),	butanoic	acid,	2,2‐dimethyl‐,1,2,3,7,8,8a‐
hexahydro‐3,7‐dimethyl‐8‐[2(tetrahydro‐4‐hydroxy‐6‐oxo‐2H‐
pyran‐2‐yl)‐ethyl]1‐naphthalenyl	 ester,	 is	 a	 lipid‐lowering	
agent	that	is	derived	synthetically	from	fermentation	products	
of	 Aspergillus	 terreus	 (Figure	 1).	 After	 oral	 ingestion	
simvastatin,	an	inactive	lactone,	is	hydrolyzed	to	corresponding	
ortho‐hydroxy	 acid	 leading	 to	 the	 inhibition	 of	 3‐hydroxy	 3‐
methyl	 glutaryl‐coenzyme	 A	 (HMG‐Co	 A)	 reductase,	 respon‐
sible	for	catalysing	the	conversion	of	HMG‐Co	A	to	mevalonate,	
which	 is	 an	 early	 and	 rate	 limiting	 step	 in	 cholesterol	
biosynthesis	[3,4].	
Recently,	U.S.	Food	and	Drug	Administration	(FDA)	[5]	has	
approved	 a	 fixed‐dose	 combination	 tablet	 consisting	 of	
sitagliptin	and	simvastatin.	This	is	the	first	product	to	combine	
a	type	2	diabetes	drug	with	a	cholesterol	lowering	drug	in	one	
tablet.	
Many	 techniques	 like	 UV‐visible	 spectrophotometry	 [6,7],	
HPLC	 [8‐13]	 and	 flourimetry [14]	have	been	 reported	 for	 the	
determination	 of	 SIT	 alone	 or	 in	presence	 of	 the	 combination	
with	other	drugs.	On	the	other	hand,	SIM	could	be	determined	
either	alone	or	in	presence	of	its	metabolites	or	in	combination	
with	 other	 drugs	 using	 different	 techniques	 like	 UV‐visible	
spectrophotometry	[15‐17],	HPLC	[18‐24]	and	LC/MS/MS	[25‐
28].	
	
	
(a)	
	
	
(b)	
	
Figure	1.	Chemical	structure	of	(a)	Sitagliptin		
(C16H15F6N5O)	and (b)	Simvastatin	(C25H38O5).	
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For	 the	 new	 co‐formulated	 dosage	 form,	 a	 few	 methods	
were	 published	 for	 the	 determination	 of	 both	 drugs	 when	
present	 in	 combination.	 These	 methods	 comprise	 the	 use	 of	
simultaneous	 equation	 spectrophotometric	 method	 [29],	 RP‐
HPLC	 [30,31]	 and	 in	 human	 plasma	 by	 LC‐MS/MS	 and	 its	
application	to	a	human	pharmacokinetic	[32].	
The	 goal	 of	 the	 present	 work	 is	 to	 develop	 validated,	
simple,	 accurate,	 precise,	 economic	 spectrophotometric	
methods	 due	 to	 its	 wide	 availability	 in	 most	 quality	 control	
laboratories	 for	 the	 simultaneous	 quantification	 of	 the	
combined	diabetes	with	cholesterol	lowering	drug	tablet.		
	
2.	Experimental	
	
2.1.	Instrumentation	
	
A	 double	 beam	 UV‐vis	 spectrophotometer	 (SHIMADZU,	
Japan)	model	UV‐1601	PC	with	matched	quartz	cell	(1	cm	path	
length)	 connected	 to	 IBM	 compatible	 computer	 and	 HP	 680	
inkjet	 printer	 (Hewlett	 Packard,	 USA).	 The	 bundled	 UVPC	
personal	 spectroscopy	 software	 version	 3.7	 was	 used;	 at	 a	
spectral	bandwidth	2	nm	and	scanning	speed	of	2800	nm/min.	
	
2.2.	Chemicals	and	materials	
	
Pure	 simvastatin	 and	 sitagliptin	 phosphate	 monohydrate	
were	 kindly	 supplied	by	Merck	 Sharp	&	Dohme	 International,	
USA.	The	marketed	 formulation	studied	was	 Juvisync™	 tablets	
manufactured	 by	Merck	 Sharp	Dohme	 International,	 USA	BNO
G011008	each	 tablet	 contains:	128.5	mg	sitagliptin	phosphate	
monohydrate	equivalent	to	100	mg	sitagliptin	free	base	and	20	
mg	 simvastatin.	 Distilled	 water	 from	 "Aquatron"	 Automotive	
water	 Still	 A	 4000	 (Bibby	 Sterillin	 Ltd.,	 Staffordshire,	 UK).	
Methanol	 from	 E.	 Merck,	 Darmstadt,	 Germany.	 Methanol	
spectroscopy	grade	is	purchased	from	El‐NASR	Pharmaceutical	
Chemicals	Co.,	Abu‐Zaabal,	Cairo,	Egypt.	
	
2.3.	Standard	Solutions	
	
Sitagliptin	 phosphate	 monohydrate	 standard	 solution	 (1	
mg/mL)	was	prepared	by	dissolving	100	mg	of	the	pure	drug	in	
30	 mL	 of	 70%	 methanol	 into	 100	 mL	 measuring	 flask	 with	
continuous	 shaking	 for	 about	 10	 minutes.	 The	 volume	 was	
completed	 to	 the	 mark	 with	 the	 corresponding	 solvent.	
Simvastatin	 standard	 solution	 (0.1	 mg/mL)	 was	 prepared	 by	
dissolving	10	mg	 of	 the	pure	base	 in	 the	 same	 solvent	 by	 the	
same	manner	to	get	the	desired	final	concentration.	
	
2.4.	Procedures	
	
2.4.1.	Linearity	
	
Aliquots	of	standard	solutions	of	SIM	(0.1	mg/mL)	and	SIT	
(1	 mg/mL)	 equivalent	 to	 20‐180	 µg	 and	 0.4‐3.6	 mg	 in	 70%	
methanol	 were	 accurately	 and	 separately	 transferred	 into	 a	
series	of	10	mL	volumetric	 flasks	and	the	volume	of	each	was	
completed	to	the	mark	with	the	same	solvent.	
For	 determination	 of	 SIT	 by	 the	 zero	 order	 method,	 the	
absorbencies	 of	 SIT	 were	 measured	 at	 266.4	 nm.	 For	
simultaneous	 determination	 of	 both	 drugs	 by	 the	 third	
derivative	method,	 the	 peak	 amplitudes	 (peak	&	 valley)	were	
measured	 at	275.3‐280.3	nm	and	240.5‐244.7	nm	 for	 SIT	and	
SIM,	respectively.	
For	simultaneous	determination	of	both	drugs	by	 the	 first	
derivative	 of	 ratio	 spectra	 method,	 the	 peak	 heights	 were	
measured	 at	 255.9	 and	 275.2	 nm	 using	 18	 µg/mL	 SIM	 as	
devisor	 to	 determine	 SIT	 in	 a	 concentration	 range	 of	 40‐360	
µg/mL	 and	 at	 228.3,	 240.5	 and	 248.0	 nm	 (peak	 amplitude)	
using	 100	 µg/mL	 SIT	 as	 divisor	 to	 determine	 SIM	 in	 a	
concentration	range	2‐18	µg/mL	SIM.	
For	determination	of	SIM	by	the	ratio	subtraction	method,	
SIM	can	be	determined	by	dividing	the	spectra	of	the	mixtures	
of	both	drugs	by	 the	spectrum	of	SIT	(40	µg/mL)	 followed	by	
subtracting	 the	 constant	 absorbance	 value	 of	 the	 plateau	 and	
finally	multiply	the	produced	spectrum	by	the	spectrum	of	the	
devisor.	
	
2.4.2.	Accuracy	
	
Accuracy	 was	 assured	 by	 carrying	 out	 the	 previously	
mentioned	procedures	under	linearity	for	the	determination	of	
different	 concentrations	 of	 pure	 SIT	 and	 SIM.	 The	
concentrations	 were	 calculated	 from	 the	 corresponding	
regression	equations.	
	
2.4.3.	Precision	
	
2.4.3.1.	Intraday	precision	(Repeatability)		
	
Three	 concentrations	 of	 each	 drug	 were	 analyzed	 three	
times	intraday	using	the	previously	mentioned	procedures.	The	
percentage	 recoveries	 of	 each	 drug	 and	 its	 relative	 standard	
deviation	were	calculated	using	the	suggested	methods.	
	
2.4.3.2.	Intermediate	precision	
	
Three	concentrations	of	each	drug	were	analyzed	on	three	
successive	days	using	the	procedure	stated	under	linearity.	The	
percentage	 recoveries	 of	 each	 drug	 and	 its	 relative	 standard	
deviation	were	calculated	using	the	suggested	method.	
	
2.4.4.	Analysis	of	marketed	formulation	
	
Ten	 tablets	 (Juvisync™	 tablets)	 were	 weighed	 and	 finely	
powdered.	An	amount	of	powdered	equivalent	to	64.25	mg	SIT	
phosphate	monohydrate	and	10	mg	SIM	was	transferred	into	a	
100	mL	round	bottom	flask;	30	mL	70%	methanol	were	added	
and	 stirred	 for	 30	 minutes	 then	 filtered	 through	 0.5	 μm	
whatman	paper	into	100	mL	measuring	flask.	The	residue	was	
washed	with	 2	 x	 20	mL	 70%	methanol,	 and	 then	 the	 volume	
was	 completed	 to	 the	mark	with	 the	 same	 solvent	 and	mixed	
well.	One	ml	of	the	resulted	solution	was	transferred	to	10	mL	
measuring	 flask	 then	 the	 volume	was	 completed	 to	 the	mark	
using	the	same	solvent	and	mixed	well.	The	general	procedure	
was	 followed	 as	 mentioned	 before	 and	 the	 concentration	 of	
drug	 was	 calculated	 from	 the	 corresponding	 regression	
equation.	
	
3.	Results	and	discussion	
	
A	fixed‐dose	of	sitagliptin	and	simvastatin	in	their	new	co‐
formulated	pharmaceutical	dosage	form	[5]	is	the	first	product	
to	combine	a	type	2	diabetes	drug	with	a	cholesterol	 lowering	
drug	 in	 one	 tablet.	 The	 aim	of	 this	work	 is	 to	 develop	 simple	
and	 accurate	 methods	 for	 the	 simultaneous	 determination	 of	
the	 new	 combination	 of	 SIT	 and	 SIM	 in	 tablets.	 Molecular	
absorption	 spectroscopy	 has	 been	 extensively	 used	 for	 the	
determination	 of	 drugs	 in	 pharmaceutical	 preparation	 with	 a	
view	to	the	development	of	analytical	methods.	The	use	of	this	
technique	 for	 pharmaceutical	 analyses	 has	 the	 inherent	
constraint	that	most	active	drugs	absorb	in	 the	UV	region	and	
exhibit	 strongly	 overlapped	 spectra	 that	 impede	 their	
simultaneous	determination.	
The	zero‐order	absorption	spectra	(D0)	of	a	mixture	of	SIT	
and	 SIM	 at	 the	 ratio	 of	 their	 presence	 in	 tablets	 showed	
overlapping	 (Figure	 2)	 which	 allows	 the	 analysis	 of	 SIT	 in	
presence	of	SIM	at	266.4	nm,	but	prevents	the	analysis	of	SIM.	
As	 SIT	 is	 soluble	 in	 water	 and	 slightly	 soluble	 in	 methanol	
while,	SIM	is	insoluble	in	water	and	freely	soluble	in	methanol	
trails	were	made	 to	 dissolve	 the	mixture	 of	 the	 two	 drugs	 in	
methanol:water	 mixture.	 Different	 ratios	 of	 methanol	 and	
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water	were	tried	and	70%	were	chosen;	which	fulfills	complete	
solubility.	 A	 calibration	 curve	 is	 constructed	 relating	 the	
absorbance	 of	 zero	 order	 spectra	 of	 SIT	 at	 266.4	 nm	 to	 the	
corresponding	 concentrations	 where	 SIM	 shows	 no	
absorbance,	the	regression	equation	is	computed.	
	
ASIT	=	0.0033C	+	0.0237					r2	=	0.9997	 	 	 (1)	
		
where	C	 is	 the	concentration	of	SIT	 in	µg/mL,	ASIT	 is	 the	peak	
amplitude	of	the	zero	order	spectrum	of	SIT	at	266.4	nm,	and	r	
is	the	correlation	coefficient.	
	
	
	
Figure	2.	 Zero	 order	 absorption	 spectra	of	10	µg/mL	 simvastatin	 (—)	and	
100	µg/mL	sitagliptin	(……).	
	
3.1.	Derivative	spectrophotometric	method	(3D)	
	
For	 further	 improvement	 of	 the	 selectivity	 to	 resolve	 the	
overlap	present	between	SIT	and	SIM	in	the	mixture,	a	simple	
third	derivative	method	(3D)	[33‐38]	is	applied.	The	method	is	
based	 on	 measuring	 the	 sum	 of	 peak	 amplitudes	 (peak	 &	
valley)	 at	 275.3‐280.3	 nm	 and	 240.5‐244.7	 nm	 (Figure	 3)	 for	
SIT	and	SIM,	respectively.		
	
	
Figure	 3.	 Third	 derivative	 spectra	 of	 10	 µg/mL	 simvastatin	 (—)	 and	 100	
µg/mL	sitagliptin	(——).	
	
The	main	instrumental	parameters	that	affect	the	shape	of	
the	 derivative	 spectra	 such	 as	 the	 speed,	 the	 wavelength	
increment	 over	 which	 the	 derivative	 is	 obtained	 (Δλ)	 and	
degree	 of	 smoothing	 were	 optimized	 to	 give	 a	 well	 resolved	
peak.	 Linearity	 relationship	 was	 obtained	 between	 the	 peak	
amplitudes	 and	 the	 concentration	 over	 the	 range	 of	 40‐360	
µg/mL	and	2‐18	µg/mL	for	SIT	and	SIM,	respectively	(Figure	4	
and	 5),	 from	 which	 the	 linear	 regression	 equation	 were	
computed	and	found	to	be:	
	
3DSIM	=	0.1156	‐	0.0217	r2	=	0.9994	for	SIM	 	 (2)	
	
3DSIT	=	0.0039	+	0.0279	r2	=	0.9995	for	SIT	 	 (3)	
	
where	3D	is	the	sum	of	peak	amplitudes	(peak	&	valley)	of	the	
spectra,	 C	 is	 the	 corresponding	 concentration	 and	 r	 is	 the	
correlation	coefficient.		
	
	
Figure	4. Third	derivative	spectra	of simvastatin	in	the	range	of	2‐18	µg/mL.
	
	
	
Figure	 5.	 Third	 derivative	 spectra	 of	 sitagliptin	 in	 the	 range	 of	 40‐360	
µg/mL.	
	
3.2.	Ratio‐spectra	derivative	spectrophotometric	method	
(DD1)	
	
As	 can	 be	 seen	 in	 Figure	 2,	 the	 absorption	 spectra	 of	 SIT	
and	SIM;	the	maximum	wavelengths	of	the	two	compounds	are	
close	 to	 each	 other	 and	 their	 spectra	 overlap	 at	 200‐260	nm;	
which	 can’t	 permits	 the	 determination	 of	 the	 cited	 drugs.	
Therefore,	 the	 simultaneous	 determination	 of	 SIT	 and	 SIM	 is	
impossible	 by	 classical	 spectrophotometry	 and	 it	 is	 necessary	
to	use	another	method	to	solve	this	problem.	
Salinas	 et	al.	 [39]	 designed	 a	 spectrophotometric	method,	
which	 is	 based	 on	 the	 derivation	 of	 the	 ratio‐spectra	 for	
resolving	 binary	 mixtures.	 The	 main	 advantage	 of	 the	 ratio‐
spectra	 derivative	 spectrophotometry	 is	 the	 chance	 of	 doing	
easy	measurements	 in	 correspondence	 of	 peaks	 so	 it	 permits	
the	use	of	the	wavelength	of	highest	value	of	analytical	signals.	
Moreover,	 the	 presence	 of	 a	 lot	 of	 maxima	 and	 minima	 is	
another	 advantage	by	 the	 fact	 that	 these	wavelengths	 give	 an	
opportunity	 for	 the	determination	of	active	compounds	 in	 the	
presence	 of	 other	 compounds	 and	 excipients	 which	 possibly	
interfere	the	assay.	In	this	method	the	absorption	spectrum	of	
the	mixture	(absorbance	at	each	wavelength)	is	divided	by	the	
absorption	 spectrum	 of	 a	 standard	 solution	 of	 one	 of	 the	
components,	 and	 the	 first	 derivative	 of	 the	 ratio	 spectrum	 is	
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obtained.	 The	 concentration	 of	 the	 other	 component	 is	 then	
determined	from	a	calibration	graph.		
The	 main	 parameters	 that	 affect	 the	 shape	 of	 the	 ratio	
spectra	 which	 are	 wavelength,	 scanning	 speed,	 the	
concentration	 of	 the	 standard	 solution	 used	 as	 a	 divisor,	 the	
wavelength	 increment	 over	 which	 the	 derivative	 is	 obtained	
and	 the	 smoothing	 function	 are	 carefully	 tested.	 Accordingly,	
the	 first	 derivative	 of	 the	 ratio	 spectra	 presented	 in	 Figure	 6	
and	 7	 for	 sitagliptin	 and	 simvastatin	 in	 the	 different	
concentration	may	provide	a	good	proof	for	this	understanding.	
Different	concentrations	of	divisor	were	also	 tried	 for	SIT	and	
SIM	 which	 give	 the	 best	 regarding	 average	 recovery	 percent	
when	 they	 were	 used	 for	 the	 prediction	 of	 SIT	 and	 SIM	
concentrations	 in	 bulk	 powder	 as	 well	 as	 in	 laboratory	
prepared	mixtures.	
	
	
Figure	6.	DD1‐Spectra	of	sitagliptin	 in	the	range	of	40‐360	µg/mL	using	18	
µg/mL	simvastatin	as	divisor.	
	
	
	
Figure	7.	DD1‐Spectra	of	simvastatin	 in	the	range	of	2‐18	µg/mL	using	100	
µg/mL	sitagliptin	as	divisor.	
	
The	method	was	 applied	by	measuring	 the	peak	height	 at	
255.9	 and	 275.2	 nm	 using	 18	 µg/mL	 SIM	 as	 devisor	 over	 a	
concentration	range	of	40‐360	µg/mL	of	SIT	(Figure	6)	and	at	
228.3,	240.5	 and	248.0	nm	using	100	µg/mL	of	SIT	as	divisor	
over	a	concentration	range	of	2‐18	µg/mL	SIM	(Figure	7).	
The	linear	regression	equations	are	found	to	be:	
	
PSIT	=	0.0086C	+	0.053	r2	=	0.9995	 	 	 (4)	
	
PSIM=	0.0120C	‐	0.0841	r2	=	0.9994		 	 	 (5)	
	
where,	C	is	the	concentration	in	µg/mL,	P	is	the	peak	amplitude	
of	 the	 first	derivative	of	 the	 ratio	 spectrum	curve	and	r	 is	 the	
correlation	coefficient.	
	
3.3.	Ratio	subtraction	method	
	
The	ratio	subtraction	technique	[40]	depends	on	that,	if	you	
have	a	mixture	of	two	drugs	X	and	Y	of	overlapping	spectra,	you	
can	 determine	 X	 by	 dividing	 the	 spectrum	 of	 the	 mixture	 by	
known	 concentration	 of	 Y	 as	 a	 divisor	 (Yʹ).	 The	 division	will	
give	 a	 new	 curve	 that	 represents	 	 (X/Y)	 +	 Constant.	 If	 we	
subtract	 this	 constant,	 then	multiply	 the	 new	 curve	 obtained	
after	 subtraction	 by	 Yʹ	 (the	 divisor),	 therefore	 we	 can	 obtain	
the	curve	of	X	again.	This	can	be	summarized	as	the	following:	
	
	=	 	=	 	+	Constant		 	 	 (6)	
	Constant	–	Constant	=	 			 	 							 (7)	
	 . 			 	 	 	 	 (8)	
This	constant	can	be	determined	directly	from	the	curve		by	
the	 straight	 line	 which	 is	 parallel	 to	 λ	 axis	 in	 this	 region.	
Practically,	 the	 ratio	 subtraction	 method	 starts	 by	 scanning	
zero‐	order	spectra	of	 the	prepared	standard	solutions	of	 SIM	
in	 70%	 methanol	 (Figure	 2),	 then	 the	 linearity	 is	 checked	
between	 absorbance	 at	 the	 selected	 wavelength	 at	 237.5	 nm	
and	 the	 corresponding	 concentration	 of	 SIM.	 The	 method	
depends	on	that,	when	a	mixture	of	SIM	(X)	and	SIT	(Y);	where	
the	 spectrum	 of	 (Y)	 is	 more	 extended	 (Figure	 2),	 the	
determination	of	(X)	could	be	done	by	scanning	the	zero	order	
absorption	 spectra	 of	 the	 laboratory‐prepared	 mixtures	 (SIM	
and	SIT),	dividing	 them	by	carefully	chosen	concentration	(40	
µg/mL)	 of	 standard	 SIT	 (Y	 =	 divisor)	 producing	 a	 new	 ratio	
spectra	 that	 represent	 (X/Y)	+	 constant	 as	 shown	 in	 Figure	 8	
then	 subtraction	 of	 the	 absorbance	 values	 of	 these	 constants	
(Y/	 Yʹ)	 in	 plateau	 as	 shown	 in	 Figure	 9,	 followed	 by	
multiplication	 of	 the	 obtained	 spectra	 by	 (Yʹ)	 the	 divisor	 as	
shown	in	Figure	10.		
	
	
Figure	8.	Absorption	spectra	of	 laboratory	prepared	mixtures	of	sitagliptin	
and	simvastatin	in	the	ratio	of	100:10	(—),	60:12	(.…)	and	40:16	(—	—).	
	
Finally,	 the	 original	 spectra	 of	 SIM	 (X)	 could	 be	 obtained	
which	are	used	for	direct	determination	of	SIM	at	237.5	nm	and	
calculation	 of	 the	 concentration	 from	 the	 corresponding	
regression	 equation.	 A	 linear	 correlation	 is	 obtained	 between	
the	absorbance	and	the	corresponding	concentration	of	SIM	at	
237.5	nm.	The	regression	equation	is:		
	
PSIM=	0.059C+0.0217	r2	=0.9999		 	 	 (9)	
	
where	C	is	the	concentration	of	SIM	in	µg/mL,	PSIM	is	the	peak	
amplitude	of	the	zero	order	spectrum	of	SIM	at	237.5	nm,	and	r	
is	 the	 correlation	 coefficient.	 On	 the	 other	 hand	 for	
determination	 of	 SIT	 alone	 a	 calibration	 curve	 is	 constructed	
relating	 the	 absorbance	 of	 zero	 order	 spectra	 of	 SIT	 at	 266.4	
nm	 to	 the	 corresponding	concentrations	where	SIM	shows	no	
absorbance.	
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Table	1.	Determination	of	simvastatin	and	sitagliptin	phosphate	monohydrate	in	laboratory	prepared	mixtures	by	the	proposed	methods.	
Claimed	Ratio	
(µg/mL)	
Simvastatin	
Ratio	Subtraction	 D3‐Method DD1‐Method
237.5	nm	 240.5‐244.7	nm 228.3	nm 240.5	nm 248	nm	
Found*	 Recovery	 Found*	 Recovery	 Found*	 Recovery	 Found*	 Recovery	 Found*	 Recovery	
10:128.5	 9.96	 99.60	 10.02	 100.20 10.08 100.80 9.95 99.50	 10.04	 100.40
12:77.1	 12.04	 100.33	 11.98	 99.83 12.01 100.08 11.94 99.50	 12.07	 100.58
16:51.4	 15.98	 99.88	 15.86	 99.13 16.05 100.31 15.97 99.81	 15.99	 99.94
Mean	±	S.D.	 99.94±0.368	 99.72±0.543 100.40±0.368 99.60±0.120 100.31±0.330
*	Average	of	three	determinations.	
	
Table	2.	Determination	of	simvastatin	and	sitagliptin	phosphate	monohydrate	in	laboratory	prepared	mixtures	by	the	proposed	methods.	
Claimed	Ratio	
(µg/mL)	
Sitagliptin	
D3‐Method	 DD1‐Method D0‐Method	
275.3‐280.3	nm	 255.9	nm 275.2	nm 266.4	nm	
Found*	 Recovery	 Found* Recovery Found* Recovery Found*	 Recovery
10:128.5	 128.40	 99.92	 128.60 100.08 128.60 100.08 128.29	 99.84
12:77.1	 77.05	 99.94	 77.15 100.06 77.04 99.92 77.12	 100.03
16:51.4	 51.51	 100.21	 51.35 99.90 51.26 99.79 51.50	 100.19
Mean	±	S.D.	 100.02±0.162	 100.01±0.099 99.93±0.145 100.02±0.175	
*	Average	of	three	determinations.	
	
Table	3.	Determination	of	simvastatin	in	pharmaceutical	formulation	and	application	of	standard	addition	technique.	
Pharmaceutical	Formulation	 Simvastatin	
Taken	
(µg/mL)	
Found	*	
%±S.D.	 Standard	Addition	Technique	
Juvisync™	tablets	containing		
20	mg	Simvastatin	and		
128.5	mg	Sitagliptin	phosphate	
monohydrate	equivalent	to		
100	mg	Sitagliptin	base	
BNOG011008.	
10.00	 101.32±0.924	
Pure	
Added	
(µg/mL)	
Pure	Found	*	(µg/mL)	 Recovery	(%)	
Ratio	
Subtr.	
D3	
DD1
Ratio	
Subtr.	
D3	
DD1	
228.3	
nm	
240.5	
nm	
248	
nm	
228.3	
nm	
240.5	
nm	
248	
nm	
2	 1.99	 2.01	 2.02	 1.99	 1.98	 99.50	 100.50	 101.00	 99.50	 99.00	
4 4.03 3.99 3.96 3.99 3.98 100.75	 99.75	 99.00	 99.75 99.50
6	 6.02	 5.98	 5.97	 5.97	 5.97	 100.33	 99.50	 99.67	 99.50	 99.50	
Mean	 100.19	 99.92	 99.89	 99.58 99.33
S.D.	 0.636	 0.520	 1.018	 0.144	 0.289	
R.S.D.	 0.635	 0.520	 1.019	 0.145	 0.291	
*	Average	of	three	determinations.	
	
	
	
	
	
Figure	9.	Absorption	spectra	of	 laboratory	prepared	mixtures	of	sitagliptin	
and	simvastatin	in	the	ratio	of	100:10	(—	),	60:12	(….)	and	40:16	(——)	after	
division	 on	 the	 spectrum	 of	 40	 µg/mL	 sitagliptin	 and	 subtraction	 of	 the	
constant	value.	
	
The	 selectivity	 of	 the	proposed	 procedures	 is	 assessed	 by	
the	 analysis	 of	 laboratory	 prepared	 mixtures	 containing	
different	ratios	of	the	two	drugs,	where	satisfactory	results	are	
obtained	over	the	calibration	ranges	as	shown	in	Tables	1	and	
2.	 The	 proposed	 procedures	 are	 also	 applied	 for	 the	
determination	of	SIT	and	SIM	in	Juvisync™	tablets.	The	validity	
of	the	proposed	procedures	is	further	assessed	by	applying	the	
standard	addition	technique	(Table	3	and	4).	Results	obtained	
by	 the	 proposed	 procedures	 for	 the	 determination	 of	 pure	
samples	 of	 SIT	 and	 SIM	 are	 statistically	 compared	 to	 those	
obtained	 by	 the	 reference	 method	 [16]	 (D2‐method	 for	
determination	of	simvastatin	at	243.5	nm).		
The	results	showed	no	significant	differences	between	the	
proposed	methods	and	the	reported	one	as	presented	in	Table	
5	 and	 6;	 the	 observed	 good	 agreement	 between	 proposed	
method	 and	 the	 reference	 method,	 The	 high	 percentage	
recoveries	 (99.33‐100.96)	 and	 low	 %R.S.D.	 (0.291‐1.337)	
values	 confirm	 the	 suitability	 of	 the	proposed	method	 for	 the	
routine	 determination	 of	 these	 components	 in	 the	 new	
combined	formulation.	
	
	
	
Figure	10. Absorption	spectra	of	laboratory	prepared	mixtures	of	sitagliptin	
and	simvastatin	in	the	ratio	of	100:10	(—),	60:12	(…..)	and	40:16	(——)	after	
division	 on	 the	 spectrum	 of	 40	 µg/mL	 sitagliptin	 and	 subtraction	 of	 the	
constant	value	then	multiplication	in	the	spectrum	of	40	µg/mL	sitagliptin.	
	
3.4.	Method	validation	
	
Validation	 was	 done	 according	 to	 ICH	 recommendations	
[41].	 Linearity	 of	 the	 methods	 was	 evaluated	 by	 analyzing	
different	 concentrations	 of	 SIT	 and	 SIM	 ranging	 between	 40‐
360	µg/mL	and	2‐18	µg/mL,	respectively	(Table	7	and	8).	Each	
concentration	was	made	in	triplicate.	The	assay	was	performed	
according	to	the	experimental	conditions.	
The	 percentage	 recovery	 was	 calculated	 for	 marketed	
formulation	by	standard	addition	of	pure	drugs	at	four	known	
concentrations	 an	 excellent	 recovery	 were	 obtained	 at	 each	
level.		
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Table	4.	Determination	of	sitagliptin	in	pharmaceutical	formulation	and	application	of	standard	addition	technique.	
Pharmaceutical	Formulation	
	
Sitagliptin	
Taken	
(µg/mL)	
Found*
%±S.D.
Standard	Addition	Technique	
Juvisync™	tablets	containing	20	mg	Simvastatin	
and	 128.5	 mg	 Sitagliptin	 phosphate	
monohydrate	 equivalent	 to	 100	mg	Sitagliptin	
base	BNOG011008.	
	
64.25	 99.18±0.896	
Pure	
Added	
(µg/mL)	
Pure	Found	*	(µg/mL) Recovery	(%)	
D0	 D3	
DD1	
D0	 D3	
DD1	
255.9	
nm	
275.2	
nm	
255.9	
nm	
275.2	
nm	
40	 40.65	 40.73	 39.75	 40.51	 101.63	 101.83	 99.38	 101.28	
80 79.21 81.24 78.98 79.96 99.01	 101.55	 98.73 99.95
120 121.01 119.40 121.11 119.84 100.84	 99.50	 100.93 99.87
Mean	 100.49	 100.96	 99.68	 100.37	
S.D. 1.344	 1.272	 1.130 0.792
R.S.D.	 1.337	 1.260	 1.134	 0.789	
*	Average	of	three	determinations.	
	
	
Table	5.	Statistical	comparison	between	the	proposed	methods	for	the	determination	of	sitagliptin	and	a	reference	method.	
Parameter	
Sitagliptin	 Reference	Method	*
D3	 DD1	 D0	
275.3‐280.3	nm	 255.9	nm 275.2	nm 266.4	nm
Mean±S.D.	 100.25±0.526	 100.39±0.650 100.42±0.547 99.96±0.381 100.12±0.489
R.S.D.	 0.525	 0.647 0.546 0.381 0.488	
n	 4	 4 4 4 4	
Variance	 0.277	 0.423 0.299 0.145 0.239	
F‐value	**	(9.55)	 1.159	 1.770 1.251 1.648 ‐	
Student's	t‐test	**	(1.943)	 0.362	 0.663 0.813 0.516 ‐	
*	Reference	colorimetric	method	 for	 the	determination	of	sitagliptin	by	condensation	of	 its	primary	amino	group	with	acetyl	acetone	and	 formaldehyde	 then	
measuring	the	produced	color	at	430	nm.	
**	Values	in	parenthesis	are	the	theoretical	values	of	t	and	F	at	p	=	0.05.	
	
	
Table	6.	Statistical	comparison	between	the	proposed	methods	for	the	determination	of	simvastatin	and	a	reference	method.	
Parameter	
Simvastatin	 Reference	Method	*	
D3‐Method	 DD1‐Method
240.5‐244.7	nm	 228.3	nm	 240.5	nm	 248	nm	
Mean±S.D.	 100.00±0.797	 100.24±0.723 100.17±0.466 100.39±0.366 100.27±0.808
R.S.D.	 0.797	 0.721 0.465 0.365 0.806	
n	 4	 4	 4	 4	 3	
Variance	 0.635	 0.523 0.217 0.134 0.653	
F‐value	**	(9.55)	 1.028	 1.249	 3.009	 4.873	 ‐	
Student's	t‐test	**	(1.943)	 0.443	 0.052	 0.210	 0.270	 ‐	
*	D2‐method	for	determination	of	simvastatin	at	243.5	nm.	
**	Values	in	parenthesis	are	the	theoretical	values	of	t	and	F	at	p	=	0.05.	
	
	
Table	7.	Assay	validation	results	of	the	proposed	methods.	
Parameter	
Simvastatin	
D3‐Method	 DD1‐Method
240.5‐244.7	nm 228.3	nm 240.5	nm 248	nm	
Accuracy	 100.00±0.797	 100.24±0.723 100.17±0.466 100.39±0.366
Specificity	and	Selectivity	 99.72±0.543	 100.40±0.368 99.60±0.120 100.31±0.330
Precision	Repeatability	*	 98.95±0.0.981	 100.96±0.961 101.34±0.694 99.32±0.0.812
Intermediate	Precision	*	 101.35±0.894	 99.17±1.013 101.54±0.0.789 100.84±0.0.741
Robustness	 99.68±0.541	 100.95±0.514	 101.07±0.941	 101.24±0.514	
Linearity,	Slope	 0.1156	 0.0946	 0.1404	 0.0866	
Linearity,	Intercept	 ‐0.0217	 0.0412	 0.0447	 0.0357	
Linearity,	Correlation	coefficient	(r)	 0.9997	 0.9997 0.9998 0.9997	
Range	(µg/mL)	 2‐18	 2‐18 2‐18 2‐18	
LOD	**	(µg/mL)	 1	 1 1 1	
LOQ	**	(µg/mL)	 2	 2 2 2	
*	Intra‐day	and	inter‐day	relative	standard	deviation	of	the	average	of	three	concentrations	of	the	studied	drug.	
**	LOD	and	LOQ	are	obtained	experimentally.	
	
	
Table	8.	Assay	validation	results	of	the	proposed	methods.	
Parameter	
Sitagliptin	
D3‐Method	 DD1‐Method	 D0‐Method	
275.3‐280.3	nm 255.9	nm 275.2	nm 275.3‐280.3	nm
Accuracy	 100.25±0.526	 100.39±0.650 100.42±0.547 99.96±0.381	
Specificity	and	Selectivity	 100.02±0.162	 100.01±0.099 99.93±0.145 100.02±0.175
Precision,	Repeatability	*	 99.51±0.1.123	 99.42±0.	594 101.91±0.426 102.01±1.094
Intermediate	Precision	*	 100.94±1.184	 99.91±0.0.694 99.12±0.0.912 10159±1.278
Robustness	 98.99±0.621	 99.34±0.895 102.37±1.024 99.63±0.845	
Linearity,	Slope	 0.0039	 0.0086	 0.012	 0.0033	
Linearity,	Intercept	 0.0279	 0.053	 0.0841	 0.0237	
Linearity,	Correlation	coefficient	(r)	 0.9997	 0.9997 0.9998 0.9997	
Range	(µg/mL)	 40‐360	 40‐360 40‐360 40‐360	
LOD	**	(µg/mL)	 20	 20 20 20	
LOQ	**	(µg/mL)	 40	 40 40 40	
*	Intra‐day	and	inter‐day	relative	standard	deviation	of	the	average	of	three	concentrations	of	the	studied	drug.	
**	LOD	and	LOQ	are	obtained	experimentally.	
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Table	9.	Results	of	accuracy	for	the	simultaneous	determination	of	simvastatin	and	sitagliptin	by	the	proposed	methods.	
Claimed	Simvastatin	
(µg/mL)	
D3‐Method	 DD1‐Method	
240.5‐244.7	nm	 228.3	nm 240.5	nm 248	nm	
Found*	 Recovery	 Found* Recovery Found* Recovery Found*	 Recovery
4	 4.03	 100.75	 4.04	 101.00	 3.98	 99.50	 4.03	 100.75	
8	 8.05	 100.63	 7.96	 99.50	 8.03	 100.38	 7.99	 99.88	
12	 11.91	 99.25	 11.97 99.75 12.03 100.25 12.05	 100.42
16	 15.90	 99.38	 16.11	 100.69	 16.09	 100.56	 16.08	 100.50	
Mean	±	S.D.	 100.00±0.797	 100.24±0.723	 100.17±0.466	 100.39±0.366	
*	Average	of	three	determinations.	
	
	
Table	10.	Results	of	accuracy	for	the	simultaneous	determination	of	simvastatin	and	sitagliptin	by	the	proposed	methods.	
Claimed	Sitagliptin	
(µg/mL)	
D3‐Method	 DD1‐Method D0‐Method	
275.3‐280.3	nm	 255.9	nm 275.2	nm 266.4	nm	
Found*	 Recovery	 Found*	 Recovery	 Found*	 Recovery	 Found*	 Recovery	
80	 79.85	 99.81	 80.96 101.20 80.79 80.79 79.69	 99.61
160	 161.51	 100.94	 160.84 100.53 161.12 161.12 159.64	 99.78
240	 240.91	 100.38	 239.15 99.65 240.68 240.68 239.87	 99.95
320	 319.58	 99.87	 320.58 100.18 319.15 319.15 321.56	 100.49
Mean	±	S.D.	 100.25±0.526	 100.39±0.650 100.42±.547 99.96±0.381	
*	Average	of	three	determinations.	
	
	
	
The	respective	%	Recovery	and	%R.S.D.s	for	the	two	drugs	
are	 shown	 in	 Table	 3	 and	 4	 where,	 the	 relative	 standard	
deviation	 is	 <1.5	 in	 the	 assay	 of	 raw	materials	 and	 tablets	 by	
the	three	proposed	method.	
Accuracy:	 The	 accuracy	 of	 the	 results	 was	 checked	 by	
applying	 the	proposed	methods	 for	determination	of	different	
samples	 of	 SIT	 and	 SIM.	 The	 concentrations	 were	 obtained	
from	the	corresponding	regression	equations.	From	which	the	
percentage	 recoveries	 were	 calculated	 with	mean	 percentage	
recovery	 shown	 in	 Table	 9	 and	 10.	 Accuracy	 of	 the	methods	
was	 further	 assured	 by	 the	 use	 of	 the	 standard	 addition	
technique,	 it	was	performed	by	addition	of	known	amounts	of	
pure	SIT	(40,	80	and	120	µg/mL)	and	SIM	(2,	4	and	6	µg/mL)	to	
known	 concentrations	 of	 the	 pharmaceutical	 preparation	
(64.25	 for	 SIT	 and	 10	 µg/mL	 for	 SIM)	 the	 resulting	mixtures	
were	 assayed,	 and	 the	 results	 obtained	 were	 compared	 with	
the	 expected	 results	 (Table	 3	 and	 4).	 The	 good	 recoveries	 of	
standard	 addition	 technique	 suggested	 good	 accuracy	 of	 the	
proposed	methods.	
Selectivity:	The	selectivity	of	the	methods	was	achieved	by	
the	 analysis	 of	 different	 laboratory	 prepared	 mixtures	 of	 SIT	
and	SIM	within	the	linearity	range.	Satisfactory	results	(Table	3	
and	4);	which	prove	that	the	proposed	methods,	in	addition	to	
its	 selectivity	 to	 the	 cited	 drug	 no	 interference	 from	 the	
presence	of	formulation	matrix.	
Robustness:	Robustness	which	is	the	prove	that	the	method	
is	 not	 affected	 by	 small	 deliberated	 change	was	 tested	 i.e.	 by	
trying	to	apply	the	proposed	methods	using	small	variation	of	
ratio	 of	 the	 solvent	 mixture	 used	 and	 the	 degree	 of	 the	
smoothing	 of	 the	 derivative	 curves	 and	 no	 effects	 was	
observed.	
Repeatability:	 Three	 concentrations	 of	 SIT	 and	 SIM	 were	
analyzed	 three	 times	 intra‐daily	 using	 the	 proposed	methods.	
The	 percentage	 recoveries	 and	 relative	 standard	 deviation	
were	calculated	(Table	7	and	8).	
Intermediate	 precision:	 The	 previous	 procedures	 were	
repeated	inter‐daily	on	three	different	days	for	the	analysis	of	
the	 chosen	 concentrations.	 The	 percentage	 recoveries	 and	
relative	standard	deviation	were	calculated	(Table	7	and	8).	
	
3.5.	Application	of	the	method	in	tablets	
	
The	proposed	methods	were	applied	for	the	determination	
of	SIT	and	SIM	 in	 their	combined	pharmaceutical	 formulation.	
Laboratory	 prepared	mixtures	were	 successfully	 tried	 for	 the	
three	 compositions	of	 tablets	 (10,	20	and	40	mg	of	 SIM)	with	
100	 mg	 of	 SIT,	 the	 results	 are	 shown	 in	 Table	 1.	 The	 high	
percentage	 recoveries	 (99.60‐100.31%)	 and	 low	%CV	 (0.099‐	
0.543)	values	confirm	the	suitability	of	 the	proposed	methods	
for	 the	 routine	 determination	 of	 these	 components	 in	 new	
combined	 formulation.	 Moreover,	 the	 proposed	 methods	 is	
proved	 to	 be	 much	 more	 sensitive	 than	 the	 published	 HPLC	
method	 [30]	 especially	 for	 SIM	 which	 is	 the	 lower	
concentration	 (linearity	 rang	 2‐18	 µg/mL;	while	 the	 reported	
method	is	20‐200	µg/mL).	
	
4.	Conclusion	
	
The	 proposed	 methods	 are	 simple	 and	 do	 not	 require	
sophisticated	technique	or	instrument.	The	methods	also,	offer	
a	practical	potential	for	the	simultaneous	determination	of	the	
cited	 drugs,	 without	 prior	 separation,	 especially	 with	 its	
advantages	 of	 acceptable	 sensitivity	 and	 high	 selectivity.	
Method	 validation	 has	 been	 demonstrated	 by	 variety	 of	 tests	
for	 linearity,	accuracy,	precision	LOD	and	LOQ.	The	developed	
methods	 have	 several	 advantages,	 as	 it	 is	 robust,	 economical	
and	much	more	sensitive	than	the	recently	published	HPLC;	in	
addition	to	its	importance	as	very	few	methods	were	reported	
in	 the	 last	 few	months	 for	 the	 first	 combination	drug	 to	 treat	
type	2	diabetes	and	high	cholesterol	in	one	tablet.	
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